Antileukemia efficacy of the dual BCL2/BCL-XL inhibitor AZD0466 in acute lymphoblastic leukemia preclinical models.

The remaining subtypes showed a trend of increasing BCL2 gene activity, accompanied by decreased BCL-XL activity ( Figure 1 D-E), whereas there was no trend of increase or decrease of MCL-1 activity across these B-ALL or T-ALL subtypes ( supplemental Figure 1 ).

also in 53,322 other papers